Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

Jennifer Wu, D. Liu, Michael Offin, Cecilia Lezcano, Jean Torrisi, Sheldon L. Brownstein, David M. Hyman, Mrinal M. Gounder, Wassim Abida, Alexander Drilon, James J. Harding, Ryan J. Sullivan, Filip Jankú, D. Welsch, Mary Varterasian, Anna Groover, Bingyu Li, Mario E. Lacouture